Reading PYXS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PYXS free→Reading PYXS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PYXS free→QuarterlyIQ Insights · PYXS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company. Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company. Dr. Sullivan’s resignation from the Board of Directors was not the…
Results of Operations and Financial Condition. On March 23, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the full year ended December 31, 2025 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective February 2, 2026, Dr. Lara Sullivan, M.D. ceased serving as the Chief Executive Officer, principal executive officer, and in any other executive capacity of Pyxis Oncology, Inc. (the “Company”). Effective February 2, 2026 (the “Effective Date”), the Board of Directors of the Company (the “Board”) appointed Tom Civik, a current director of…
Other Events. The Company today announced positive preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM), in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The cutoff for all data reported below is as of November 3, 2025. Monotherapy The…
of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.
of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 1, 2025, Pamela Connealy, the Chief Financial Officer and Chief Operating Officer of Pyxis Oncology, Inc. (the “Company”), retired from the Company. Ms. Connealy’s retirement from the Company was not the result of any disagreement with the Company’s independent auditors or any member of management on any matter of accounting principles or p…
Results of Operations and Financial Condition. On May 15, 2025, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the Quarter ended March 31, 2025 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On March 18, 2025, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the full year ended December 31, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer. His resignation will be effective as of March 18, 2025 and is not associated with, or attributable to, any disagreement regarding any matter related to the Company's operations, policies or practices…
Other Events. On February 26, 2025, Pyxis Oncology, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-…
Other Events. On February 4, 2025, Pyxis Oncology, Inc. issued a press release announcing the initiation of a Phase 1/2 combination trial, PYX-201-102, with PYX-201 and Merck’s Keytruda® (pembrolizumab) in multiple solid tumors. In addition, the Part 2 monotherapy expansion cohorts of the ongoing Phase 1 PYX-201-101 study have begun enrolling patients. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. KEYTRUDA ® is a registered trademark of Merck Sha…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.